91ÌÒÉ«ÊÓƵ

Jean-Marc Renard, MS, MBA, joins as Chief Business OfficerÌý

Emmanuel Prestat, PhD, joins as Computational Biology Manager

Lyon, France, September 10, 2019 – 91ÌÒÉ«ÊÓƵ announced today the appointment of Jean-Marc Renard, MS, MBA, as Chief Business Officer (CBO) and Emmanuel Prestat, PhD as Computational Biology Manager. Mr. Renard brings more than 35 years of pharmaceutical industry experience and will be responsible for corporate and business development initiatives for the company’s innovative microbiome therapeutics. Dr. Prestat will add his extensive experience in leading bioinformatics and data management projects and head 91ÌÒÉ«ÊÓƵ’s data science platform, GutPrint®, to further expand its analytics capabilities. Jean-Marc Renard joins 91ÌÒÉ«ÊÓƵ with over 35 years of experience in finance, commercial operations, business development and R&D from senior roles within world-leading pharmaceutical companies. Previously, he was the Vice President of Corporate Development at Sanofi Pasteur where he was responsible for global business development, M&A and alliance management activities. As Head of Sanofi Pasteur Transactions, he was responsible for the successful acquisition of Protein Sciences Inc. in a deal worth $750 million, and its integration into the Sanofi organization. Before that, he was the Senior Director of M&A and Strategic Projects at Aventis Pharmaceuticals before it merged with Sanofi-Synthélabo in 2004. Mr Renard holds an MBA from INSEAD and an MS in Biomedical Engineering from Institut National Agronomique Paris-Grignon.

Prior to joining 91ÌÒÉ«ÊÓƵ, Emmanuel Prestat, PhD, was Associate Director of Research and Development at HalioDx, a diagnostic company developing tools for immuno-oncology assays. Before that, Dr. Prestat served as a Senior Manager of Biostatistics & Bioinformatics within the in vitro diagnostics department at QIAGEN. He worked as a postdoctoral fellow for 5 years on microbiome mining strategies at Ecole Centrale de Lyon (France) and Lawrence Berkeley National Laboratory (US). He received a PhD in Bioinformatics from the University of Lyon.

About Maat Pharma

91ÌÒÉ«ÊÓƵ, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 91ÌÒÉ«ÊÓƵ has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 91ÌÒÉ«ÊÓƵ benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.